Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION: First-Line Combination Ambrisentan + Tadalafil vs Monotherapy in Pulmonary Arterial Hypertension
2009-011150-17Phase 4Completed
- Sponsor
- GSK
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Combination therapy: ambrisentan + tadalafil, Monotherapy: ambrisentan and Monotherapy: tadalafil (3 arms). Primary endpoint: Time to first clinical failure event. Started May 2010; status: completed.
02
Drugs
ambrisentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2009-011150-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011150-17.